Liraglutide as an Adjunct Therapy to Insulin in Type 1 Diabetes

• Research type

  Research Study

• Full title

  The efficacy and safety of Liraglutide as adjunct therapy to insulin in the treatment of Type 1 diabetes. A 52-week randomised, treat-to-target, placebo- controlled, double-blinded, parallel-group, multinational, multi-centre trial.

• IRAS ID

  125874

• Contact name

  John McKnight

• Contact email

  john.mcknight@nhs.net

• Sponsor organisation

  Novo Nordisk

• Eudract number

  2012-003580-21

• REC name

  Scotland A REC

• REC reference

  13/SS/0064

• Date of REC Opinion

  30 May 2013

• REC opinion

  Further Information Favourable Opinion